



## Common Drug Review <sup>1</sup> Submission Status

**Product:** Eliquis  
**Generic Name:** apixaban  
**Manufacturer:** Bristol-Myers Squibb Canada (BMS) and Pfizer Canada Inc.  
**Indication:** Thromboembolic events prevention, (atrial fibrillation)  
**Submission Type:** Pre-NOC PR - New Indication  
**Date Submission Received:** 2012-Sep-25      **Date NOC Issued:** 2012-Dec-05  
**Original Targeted CDEC Meeting:** 2013-Feb-20      **Priority Review Granted:** Granted

Phase		Target Time (Business Days)	Target Date <sup>2</sup>	Actual CDR Date	Comments
1	Submission deemed complete	10	2012-Oct-10	2012-Oct-10	- Pre-NOC Priority Review assessments require 10 days
2	Patient group input submission received <sup>3</sup>		2012-Oct-15	2012-Oct-15	- Call for patient input posted on 2012-Sep-07 - Patient group input deadline: 2012-Oct-15 - Patient group input submission received
3	CADTH Reviewers' Reports sent to Manufacturer <sup>4</sup>	45	2012-Dec-24	2013-Jan-14	- New target date: 2012-Dec-21 - New target date: 2013-Jan 14
4	Comments from Manufacturer on Reviewers' Reports Received by CADTH	7	2013-Jan-10	2013-Jan-23	- New target date: 2013-Jan-09 - New target date: 2013-Jan-23
5	CDEC Meeting		2013-Feb-20	2013-Feb-20	
6	CDEC Recommendation Sent to Drug Plans and Manufacturer	5 to 7	2013-Feb-27	2013-Feb-27	
7	Embargo Period <sup>5</sup> Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation	10	2013-Mar-13	2013-Mar-13	
8 (a)	Final Recommendation sent to Drug Plans and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2013-Mar-20	2013-Mar-20	- Notice of Final Recommendation issued
OR					
8 (b)	Clarification and Final Recommendation sent to Drug Plans and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
OR					
8 (c)	Placed on CDEC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
9	Final Recommendation sent to Drug Plans and Manufacturer	5			

<sup>1</sup> Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.

<sup>2</sup> The target dates for this report are based on the CDEC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).

<sup>3</sup> The deadline for Patient Group Input is 15 business days after CADTH receives the Submission or up to 25 business days if advance notice of a Submission is received from the Manufacturer.

<sup>4</sup> Target time is calculated, based on the date the Reviewers receive copies of the Manufacturer's Submission. Target time does not include the time allocated for receipt of Manufacturer's binders (5 business days) and time allocated for distribution of binders to reviewers (3 business days).

<sup>5</sup> The Recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of Final Recommendation.

This Submission Status Report reflects status as of Thursday noon.